Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.75% | -25.46% | -3.80% | 8.68% | -37.81% |
| Total Depreciation and Amortization | -- | -100.00% | -- | -100.00% | -88.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.80% | -12.60% | 99.33% | -30.20% | 1,586.05% |
| Change in Net Operating Assets | 3.40% | -191.53% | 151.72% | 117.10% | -157.24% |
| Cash from Operations | -32.01% | -75.98% | 14.80% | 34.25% | -41.25% |
| Capital Expenditure | -- | 100.00% | 0.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,203.60% | 83.32% | -280.87% | -- | -- |
| Cash from Investing | -1,203.75% | 83.32% | -280.97% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 32,043.54% | -79.00% | -49.71% | 69,500.00% | -99.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 35,206.80% | -79.00% | -49.71% | 69,500.00% | -99.99% |
| Foreign Exchange rate Adjustments | -150.29% | 210.32% | -132.02% | 16,033.33% | 100.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.61% | 49.77% | -443.56% | 174.79% | -132.41% |